Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1
Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1 · Investor's Business Daily

In This Article:

Novo Nordisk will pay Lexicon Pharmaceuticals up to $1 billion to license its experimental obesity treatment.